Evidence
Evidence-led adoption for bladder cancer pathway change.
Progen Diagnostics supports healthcare organisations with clinical evidence, pathway modelling and implementation materials for the governed adoption of Uromonitor® in bladder cancer surveillance pathways.
Making the case for Uromonitor.
Review the clinical studies and supporting pathway evidence behind Uromonitor® and Digital Uromonitor® in bladder cancer surveillance, molecular detection and faster diagnostic pathway adoption.
Digital Uromonitor® two-year recurrence risk stratification
Prospective multicentre evidence evaluating Digital Uromonitor® as a complementary tool to cystoscopy for two-year recurrence risk assessment in NMIBC.
View report →Digital PCR-Based Uromonitor for molecular detection of bladder cancer
Multicentre validation study comparing digital PCR Uromonitor with quantitative PCR and urine cytology.
View study →Digital Uromonitor® outperforms qPCR Uromonitor and cytology
EVALUATION-CUETO study showing Digital Uromonitor® performance in NMIBC surveillance compared with qPCR and cytology.
View paper →Surveillance of low-grade non-muscle-invasive bladder tumours using Uromonitor
Peer-reviewed SOLUSION trial article supporting Uromonitor’s role in low-grade NMIBC surveillance.
View study →Making the case for Uromonitor in faster diagnosis pathways
Supporting pathway paper showing how Uromonitor® may help reduce surveillance-driven cystoscopy pressure, release clinical capacity and support faster cancer diagnosis pathway objectives.
View pathway paper →
A clinical evidence library for decision-makers.
NHS organisations, private providers, laboratories and clinicians need more than marketing claims. They need clear evidence, clinical context, pathway modelling and implementation material that supports safe, governed decision-making.
Peer-reviewed studies
Published and supporting clinical papers help healthcare teams understand the evidence base for Uromonitor® and Digital Uromonitor® in bladder cancer pathways.
Pathway evidence
Evidence packs can support internal review of cystoscopy pressure, surveillance demand, service capacity and faster diagnosis pathway objectives.
Implementation documentation
Adoption should be supported by pathway rules, governance documents, audit plans and clear clinical-use boundaries.
What healthcare teams can review.
Progen Diagnostics can support clinical, operational and procurement conversations with evidence-led material designed for serious healthcare decision-making.
Clinical summary
Clear explanation of Uromonitor and its intended pathway role.
Performance data
Review of test performance and relevant clinical evidence.
Pathway model
Impact on cystoscopy demand, capacity and pathway cost.
Governance model
Rules for patient selection, escalation and clinical interpretation.
Implementation review
Material for clinicians, laboratories and operational decision-makers.
Evidence should support both clinical confidence and operational value.
For a pathway change to be credible, evidence must connect test performance with real implementation questions: who should be tested, how results are interpreted, when cystoscopy is prioritised and how outcomes are monitored.
Evidence is strongest when linked to implementation governance.
Uromonitor should be reviewed as part of a governed clinical pathway, not as a standalone consumer screening product. Evidence should support safe adoption, clear escalation rules and measurable pathway outcomes.
Discuss the evidence behind Uromonitor.
Speak to Progen Diagnostics to review Uromonitor evidence, pathway modelling and implementation materials for NHS, private provider or laboratory adoption.